Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20526115 | 0.81 | BACE1 (0.51) | BACE1GPR3ELANEALDH1A1TSHR | |
| SCHEMBL411657 | 0.74 | CYP1A2 (0.45) | BACE1GPR3ALDH1A1CYP1A2HPGD | |
| SCHEMBL9479380 | 0.73 | KCNH2 (0.36) | GPR3ATMKIF11HPGDPOLB | |
| SCHEMBL5751117 | 0.71 | TNKS2 (0.40) | GPR3ELANEALDH1A1CYP1A2HPGD | |
| SCHEMBL1826639 | 0.69 | MAOA (0.41) | GPR3ALDH1A1TSHRTDP1CYP1A2 | |
| SCHEMBL9479290 | 0.69 | CYP1A2 (0.38) | BACE1GPR3ALDH1A1TSHRTDP1 | |
| SCHEMBL6179959 | 0.69 | GPR3 (0.37) | GPR3ALDH1A1TSHRTDP1CYP1A2 | |
| SCHEMBL442600 | 0.69 | IDO1 (0.39) | GPR3ALDH1A1TDP1CYP1A2HPGD | |
| SCHEMBL1146962 | 0.69 | NCF1 (0.47) | BACE1GPR3ALDH1A1TSHRTDP1 | |
| SCHEMBL4461176 | 0.69 | GPR3 (0.37) | GPR3ALDH1A1TSHRTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735577-B2 | 1,3,5-triazine derivative, process for producing same, and organic electroluminescent element comprising same as constituent component | TOSOH CORPORATION (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2351750-B1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME AS CONSTITUENT | TOSOH CORP (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20110190494-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | TOSOH CORPORATION (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-2351750-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | Tosoh Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190494-A1 | 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AS CONSTITUENT COMPONENT | ASH2L, SETDB1, KAT5 | BACE1 3466/4885GPR3 1757/4885ATM 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.